Liquid multiomics to tailor systemic treatment for malignant pleural mesothelioma
Official title: Liquid multiomics for personalized systemic treatment in malignant pleural mesothelioma
Funded at Baylor College of Medicine · NIH-11414823 · Data updated 2026-11-12
Researchers are testing liquid biomarkers to help choose personalized treatments for people with malignant pleural mesothelioma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | August 1, 2026 |
| Project end | July 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $663,998 |
| NIH project number | 1R01CA314931-01 |
| Project ID | NIH-11414823 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with malignant pleural mesothelioma who are candidates for systemic therapy and willing to provide blood samples for biomarker analysis.
✕Less likely to help
Patients whose disease biology does not align with the identified biomarkers or who are not receiving systemic therapy may see limited or no benefit.
What this research studies
Malignant pleural mesothelioma is a rare, aggressive cancer that often resists current therapies. This project aims to identify and validate blood-based biomarkers (liquid biomarkers) that can guide which systemic treatments will work best for individual patients. The team will combine measures such as MHC genotype and SMRP levels to predict survival and monitor disease progression, using a predictive model validated in patient cohorts. The goal is to enable more precise, effective treatment strategies and better outcomes for people with this cancer.
Why it matters
Potential benefit: If successful, patients could receive more personalized, potentially more effective systemic therapies for mesothelioma based on a simple blood-based test.
How similar studies have gone: Previous work suggests liquid biomarkers can reflect disease status and treatment response, supporting the potential of biomarker-guided therapy in mesothelioma.
Where this research is happening
-
Baylor College of Medicine
Houston, United States Active
Researchers
- Principal investigator: Lee, Hyun-Sung — Baylor College of Medicine
- Study coordinator: Lee, Hyun-Sung
Related research
Other NIH-funded projects on the same topics.
-
National Mesothelioma Biobank expands patient biospecimen and data sharing for research
A national biobank collects blood, tissue, and clinical data from mesothelioma patients to help researchers develop better diagnostics and treatments.
-
Intraperitoneal CAR T cells for peritoneal mesothelioma
A new approach uses CAR T cells delivered directly into the abdominal cavity to target mesothelioma, aiming to help people whose disease is confined to the abdomen.
-
New ways to make mesothelioma treatment work better
This project looks at whether common antidepressant drugs plus a drug that blocks Mcl-1 can help chemotherapy work better for people with malignant mesothelioma.
-
Targeting mitochondria to help immunotherapy work better for pleural mesothelioma
The team will try medicines that change cancer cell mitochondria to help immunotherapy work better for people with malignant pleural mesothelioma.
-
Tumor-targeted imaging and alpha-particle therapy for mesothelioma
This project develops an antibody-based imaging approach and a targeted alpha-particle therapy to find and kill mesothelioma tumors, including hard-to-treat sarcomatoid cases.
-
Photofrin and heme oxygenase–boosting drugs for pleural mesothelioma
This work looks at whether Photofrin and drugs that boost heme oxygenase can slow tumor growth in people with malignant pleural mesothelioma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.